ESMO Immuno-Oncology Congress 2023
![Aurélien Marabelle](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/aurelien-marabelle/18674385-1-eng-GB/aurelien-marabelle_i770.jpg)
Is TMB a good predictive biomarker for immunotherapy?
Evidence is compelling, but utility may depend on the clinical context
![ESMO-Immuno-Oncology-2023_Audience_02](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-immuno-oncology-2023/esmo-immuno-oncology-2023_audience_02/18674474-1-eng-GB/esmo-immuno-oncology-2023_audience_02_i770.jpg)
TILs show long-term efficacy in melanoma, but predicting treatment response is still a challenge
After proof of efficacy in patients with melanoma in a clinical trial, major efforts are now directed to make the use of TILs easier and safer in clinical practice.
![ESMO-Immuno-Oncology-2023_Jarushka_Naidoo](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-immuno-oncology-2023/esmo-immuno-oncology-2023_jarushka_naidoo/18674373-1-eng-GB/esmo-immuno-oncology-2023_jarushka_naidoo_i770.jpg)
Lenvatinib plus pembrolizumab does not improve outcomes in NSCLC
Certain immunotherapy combinations that are effective in selected solid tumours may not be effective in lung cancer without targetable genetic alterations.
![ESMO-Immuno-Oncology-2023_Venue](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-immuno-oncology-2023/esmo-immuno-oncology-2023_venue/18669844-1-eng-GB/esmo-immuno-oncology-2023_venue_i770.png)
Blocking GDF-15 may be promising to overcome resistance to immunotherapy
A study reports evidence of antitumour activity by combining a GDF-15 neutralising antibody with PD-1 inhibition in cancers that are refractory/relapsed to immune checkpoint inhibitors
![Challenges in cell-based immunotherapies create opportunities for progress](/var/esmo/storage/images/esmo-daily-reporter/esmo-immuno-oncology-congress-2023/highlights/challenges-in-cell-based-immunotherapies-create-opportunities-for-progress/18666437-1-eng-GB/challenges-in-cell-based-immunotherapies-create-opportunities-for-progress_i770.png)
Challenges in cell-based immunotherapies create opportunities for progress
According to the 2023 ESMO Immuno-Oncology Awardee, Steven A. Rosenberg, the keys to progress are identifying the optimal characteristics of antitumour effector lymphocytes, cancer antigen identification and strategies for overcoming resistance mechanisms to enhance immune-cell function